Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients by Chuan-Mo Lee et al.
RESEARCH ARTICLE Open Access
Peripheral blood toll-like receptor 4
correlates with rapid virological response to
pegylated-interferon and ribavirin therapy
in hepatitis C genotype 1 patients
Chuan-Mo Lee1,2, Tsung-Hui Hu1,2, Sheng-Nan Lu1,2, Jing-Houng Wang1,2, Chao-Hung Hung1,2,
Chien-Hung Chen1,2 and Yi-Hao Yen1,2*
Abstract
Background: Toll-like receptors (TLRs) are effectors of the innate immune system that are able to recognize hepatitis C
virus (HCV) and give rise to an immune response. Failure of interferon (IFN)-α-based treatment is related to host
immunity. Therefore, we sought to study the clinical importance of TLRs in HCV genotype 1 patients who received
pegylated IFN (PEG-IFN) plus ribavirin (RBV) therapy.
Methods: We enrolled 79 treatment-naïve patients with HCV genotype 1. Patients completed a 24- to 48-week
course of response-guided therapy. Peripheral blood monocyte (PBMC) expression of mRNA for TLRs 2, 3, 4, 7,
and 9 was quantified by real-time PCR before therapy. TLR mRNA expression is shown as a log ratio relative to
GAPDH mRNA (log 2 -(ΔCt)).
Results: Forty-five patients (57.0 %) showed a rapid virological response (RVR). Univariate analysis revealed that
TLR 2, 3, 4, 7, and 9 were significantly lower in the RVR group than in the non-RVR group (P = 0.001, 0.014, < 0.001, 0.
008, and 0.001, respectively). Multivariate analysis revealed that TLR 4 < −2 log (OR: 7.17, 95 % CI: 1.70–30.34, P = 0.
007) was an independent predictor for RVR. In addition, levels of TLR 2, 3, 4, 7, and 9 were positively correlated
with HCV viral load (P = 0.009, 0.013, < 0.001, 0.007, and 0.001, respectively).
Conclusions: A low level of TLR 4 mRNA in PMBCs was correlated with RVR, which indicates that TLR4 may play
a critical role in HCV recognition and activation of innate immunity. TLR expression levels were correlated with
HCV viral load, indicating that TLR activation upon exposure to HCV may subsequently limit HCV replication.
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Background
Hepatitis C virus (HCV) is a blood-borne, hepato-
trophic virus that establishes a chronic HCV infection
in up to 85 % of cases [1]. With an estimated 2 % of the
global population infected with HCV [2], which carries
the potential for chronic infection leading to cirrhosis,
end-stage liver diseases, and hepatocellular carcinoma
(HCC), it poses a considerable health risk [3–6].
Non-alcoholic fatty liver disease (NAFLD) is now in-
creasingly being recognized as a cause of end-stage liver
disease and is associated with increased rates of HCC,
liver transplantation, and death [7–9]. Current popula-
tion based prevalence of NAFLD is approximately 70 %
in people with type 2 diabetes mellitus (DM) [10]. Fur-
ther, a recent study showed that liver transplant recipi-
ents with non-alcoholic steatohepatitis (NASH) have a
higher risk of de novo post-transplant DM. This suggests
the presence of an underlying metabolic disorder beyond
fatty liver that may be causative for both NASH and type
2 diabetes [11].
* Correspondence: cassellyen@yahoo.com.tw
1Division of Hepatogastroenterology, Department of Internal Medicine,
Kaohsiung Chang Gung Memorial Hospital, 123 Ta Pei Road, Niao Sung Dist.
833, Kaohsiung City, Taiwan
2School of Medicine, College of Medicine, Chang Gung University, Taoyuan,
Taiwan
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lee et al. BMC Gastroenterology  (2016) 16:73 
DOI 10.1186/s12876-016-0492-6
Infection with HCV genotype 1, the prevalent geno-
type in Taiwan, Japan, and Southern and Eastern Europe
[12–16], is predictive of a poor response to interferon
(IFN)-based therapy. The sustained virological response
(SVR) is 50–80 % following combination therapy with
pegylated interferon (peg-IFN) plus ribavirin (RBV) for
48 weeks [17–20].
The European Association for the Study of the Liver
(EASL) and the American Association for the Study of
Liver Diseases (AASLD) guidelines [21, 22] both sug-
gest direct antiviral agents (DAAs) as the first line of
therapy for patients infected with genotype 1. However,
the SVR rate can reach 76 % after 48 weeks of peg-IFN
plus RBV therapy in Taiwanese patients with genotype
1 [20], and peg-IFN plus RBV therapy remains the
standard of care in Taiwan. Therefore, it is crucial to
determine the mechanism of treatment failure for IFN-
based therapy in Taiwan.
Host immunity is an important factor that is related to
the failure of IFN-α-based treatment. The innate im-
mune system is particularly relevant in viral infections
[23]. Toll-like receptors (TLRs), as effectors of the innate
immune system, are activated immediately upon expos-
ure to infectious agents and may subsequently limit rep-
lication of infectious agents [24].
TLRs belong to a family of cell receptors that are present
on mammalian cells, and that are able to recognize several
pathogen-associated molecular patterns (PAMPs) present
on microbes [25]. Various viral components (RNA, viral
proteins, and intact virions) can be recognized as PAMPs
by the immune system; recognition can give rise to an im-
mune response [25], including up-regulation of IFN-α pro-
duction [23]. This may induce enhanced expression of
IFN-α-inducible genes, most of which perform important
antiviral and immune regulatory functions. In vitro studies
have indicated that, of the 11 human TLRs identified so
far, TLR 2, 3, 4, 7, and 9 recognize specific HCV viral com-
ponents as PAMP ligands [26–33].
Whether TLR expression is associated with a virological
response in patients infected with HCV genotype 1 re-
mains unclear. In this study, we investigated whether TLR
expression on peripheral blood monocytes (PBMCs) is as-
sociated with virological responses to peg-IFN plus RBV
therapy in patients infected with HCV genotype 1.
Methods
Patients
We enrolled 79 treatment-naïve patients with HCV geno-
type 1, who then completed a 24- to 48-week course of
response-guided therapy (RGT) with peg-IFN plus RBV.
The RGT received was simply part of standard care in
Taiwan and was funded by the Bureau of National Health
Insurance, Department of Health, Taiwan. RGT was per-
formed as follows: 24-week therapy for patients with rapid
virological response (RVR) (defined as undetectable
HCV RNA at week 4); 48-week therapy for patients
with early virological response (EVR) (defined as de-
tectable HCV RNA at week 4 and a > 2-log decrease in
HCV RNA at week 12); therapy was stopped at week 12
for patients with a null response (defined as a > 2-log
decrease in HCV RNA at week 12). PegIFN α-2b (Peg-
Intron, Schering-Plough Corporation, Kenilworth, NJ)
at 1.5 μg/kg or PegIFN α-2a (Pegacys, Roche, Basel,
Switzerland) at 180 μg was given subcutaneously once
weekly. RBV was given at 1000 mg/day for patients
with a body weight of ≤ 75 kg and 1200 mg/day for
those > 75 kg. Forty five patients achieved RVR, 34 pa-
tients did not. The characteristics of non-RVR group
patients were as follow: there were 19 male and 15 fe-
male, the median age was 53.4 years, the median body
mass index (BMI) was 26.4 Kg/m2, the median Alanine
Aminotransferase (ALT) was 84.5 IU/L, 28 patients had
high viral load (≥ 4 × 105 IU/ml), 6 patients had liver
crrhosis, 24 patients had rs12979860 CC genotype, and
24 patients with good drug adherence.
Patients who were positive for anti-HCV antibody,
assessed by third-generation enzyme-linked immuno-
sorbent assay, were diagnosed with chronic hepatitis C;
the diagnosis was confirmed by detection of serum
HCV-RNA. Patients were excluded if they tested positive
for serum hepatitis B surface antigens, anti-HIV anti-
bodies, or exhibited other causes of hepatocellular injury
(e.g., any history of alcoholism, autoimmune hepatitis,
primary biliary cirrhosis, or treatment with hepatotoxic
drugs).
HCV RNA was qualitatively detected using a PCR-
based assay (Cobas Amplicor Hepatitis C Virus Test,
version 2.0, Roche Molecular Systems, Branchburg, NJ,
USA), which has a lower limit of detection of approxi-
mately 50 IU/mL. HCV RNA was quantified by real-
time PCR-based assay (COBAS AmpliPrep/COBAS
TaqMan HCV Test, Roche), with a dynamic range of
43 to 69,000,000 IU/ml. Genotyping of HCV was per-
formed using a Siemens Diagnostics Versant HCV
Genotype Assay. SVR was defined as serum HCV RNA
undetectable at week 24 after treatment.
PBMC preparation and RNA extraction
PBMCs were isolated by Ficoll-Hypaque density gradi-
ent centrifugation from the peripheral venous blood of
the subjects before antiviral therapy. Total cellular
RNA was extracted using the TRizol Reagent (Invitro-
gen, Carlsbad, CA) in accordance with the manufac-
turer’s instructions. RNA yield and purity were
determined by measuring the absorbance at 260/
280 nm on a NanoDrop spectrophotometer (Thermo
Fisher Scientific, Waltham, Massachusetts, USA).
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mRNA expression of TLR genes in PBMCs
To quantify mRNA expression of TLR genes (including
TLR 2, 3, 4, 7, and 9) in PBMCs, we performed quanti-
tative reverse transcription polymerase chain reactions
(QRT-PCR) with a LightCycler 480 system (Roche
Diagnostics GmbH, Mannheim, Germany). The reagent
mixture was prepared according to the protocol pro-
vided by the manufacturer (Roche Diagnostics GmbH,
Mannheim, Germany). Total RNA (2 μg) was extracted
from PMBCs and cDNA was generated using an oli-
go(dT)18 primer (GeneMark Taiwan). PCR was performed
in a 10-μl reaction mixture containing 2× LightCycler 480
SYBR Green I Master mix (5 μl) (Roche Diagnostics
GmbH, Mannheim, Germany), forward and reverse
primers (0.5 μM each), and cDNA (1 μl). The conditions
for amplification were as follows: one cycle of 95 °C for
10 min and 40 cycles of 95 °C for 10 s, 60 °C for 12 s, and
72 °C for 20 s. After amplification was completed, a final
melting-curve analysis was performed by denaturation at
95 °C, re-annealing at 65 °C for 1 min, and then slow heat-
ing (0.1 °C/s) to 95 °C to determine the product-specific
melting temperature. The reaction chamber was then
cooled to 40 °C for 30 s prior to opening the chamber to
remove the plate, as recommended by the manufacturer.
Data were analyzed using the LightCycler Software 1.5
(Roche Diagnostics GmbH, Mannheim, Germany). The
threshold cycle value (Ct) was determined using the fol-
lowing equation: ΔCt = Ct (target gene) - Ct (GAPDH).
The expression of target genes in each sample was tested
in triplicate. mRNA expression of target genes is shown as
a log ratio relative to GAPDH mRNA (log 2 -(ΔCt)).
Genetic variation in interleukin (IL)28B
Patient IL28B genotypes ere determined with ABI Taq-
Man SNP genotyping assays (Applied Biosystems, Foster
City, CA) and with predesigned commercial genotyping
assays (ABI assay ID: C__11710096_10). Briefly, PCR
primers and two allele-specific probes were designed to
detect a specific Single-nucleotide polymorphism (SNP)
target. PCR reactions were performed in 96-well micro-
plates with a StepOnePlus™ Real-Time PCR System (Ap-
plied Biosystems). Allele discrimination was achieved by
fluorescence detection using the StepOne™ Software v2.1.
Statistical analysis
We analyzed differences between virological responders
and non-responders using the chi-square test and Stu-
dent’s t-test. Independent factors that may have influenced
the response to combination therapy were identified using
stepwise multiple logistic regression analysis. We used
Pearson’s correlation coefficient analysis to evaluate the
correlation between mRNA expression of TLRs and
baseline clinical variables. A P-value of <0.05 was con-
sidered statistically significant.
Results
Comparison of baseline features in patients with RVR
and non-RVR
Forty-five patients (57 %) achieved RVR. The proportion of
patients with a low viral load (< 4 × 105 IU/ml), rs12979860
CC genotype, and rs8099917 TT genotype was higher in
the RVR group than in the non-RVR group. In addition,
the median body mass index (BMI) was lower and mRNA
expression of TLR 2, 3, 4, 7, and 9 was lower in the RVR
group, compared with the non-RVR group.
There were no significant differences between the RVR
and non-RVR patient groups in terms of gender, ALT
levels, rates of adherence to treatment, or the proportion
of patients with liver cirrhosis (Table 1).
Multivariate analysis of pretreatment factors associated
with RVR
Stepwise multiple logistic regression analysis revealed
that mRNA expression of TLR 4 < −2 log (odds ratio
(OR), 7.17; 95 % confidence interval (CI), 1.70–30.34;
P = 0.007), a viral load <4 × 105 IU/ml (OR, 7.08; 95 % CI,
1.17–30.09; P = 0.008), and rs 8099917 TT genotype (OR,
38.8; 95 % CI, 2.65–568.63; P = 0.008) were independent
predictors for RVR.
Comparison of baseline features in patients with SVR
and non-SVR
Four patients who completed the treatment but not the
follow-up were excluded. The remaining 75 patients
were analyzed. Of these 75 patients, 45 (60 %) achieved
SVR. The proportion of males and the rate of liver cir-
rhosis were both lower in the SVR group than in the
non-SVR group. The proportion of patients with RVR,
rs 12979860 CC genotype, and rs 8099917 TT genotype
were higher in the SVR group than in the non-SVR
group. There were no significant differences between the
SVR and non-SVR patient groups in terms of TLR ex-
pression (Table 2).
Multivariate analysis of pretreatment factors associated
with SVR
Stepwise multiple logistic regression analysis revealed
that non-liver cirrhosis (OR, 6.94; 95 % CI, 1.22–40.0;
P = 0.029), rs 12979860 CC genotype (OR, 6.53; 95 %
CI, 1.18–36.01; P = 0.031), and RVR (OR, 3.06; 95 %
CI, 1.01–9.28; P = 0.048) were independent predictors
for SVR.
Lee et al. BMC Gastroenterology  (2016) 16:73 Page 3 of 6
Correlation between mRNA expression of TLRs
and baseline clinical features
mRNA expression of TLR 2, 3, 4, 7, and 9 was correlated
with HCV viral load, but was not correlated with ALT
levels or liver cirrhosis (Table 3).
Discussion
In this study, we found that low TLR4 mRNA expres-
sion in PBMCs was associated with RVR in patients
with HCV genotype 1 who received peg-IFN and RBV
therapy. Univariate analysis also revealed that TLR 4
expression is lower in the SVR group than in the non-
SVR group (P = 0.067), although it is not statistically
significant. The case number in our study is limited,
may be more case number is needed to reach statisti-
cally significant.
TLR4, a lipopolysaccharide-receptor, plays a critical
role in pathogen recognition and activation of innate
and adaptive immunity. Ten et al. studied the release of
soluble TLR2 and TLR4 in plasma of 394 patients with
infections (infectious mononucleosis, measles, respira-
tory tract infections, bacterial sepsis and candidemia) or
Table 1 Comparisons of baseline features of patients with rapid virological response (RVR) and those with non-RVR
Variables RVR (N = 45) Non-RVR (N = 34) P value
Sex (M:F) 23:22 19:15 0.674
Age (median,IQR) 60.5 (52.9 ~ 67.8) 53.4 (43.9 ~ 63.0) 0.003
BMI, Kg/m2 (median,IQR) 23.5 (21.8 ~ 24.7) 26.4 (23.0 ~ 29.4) 0.001
ALT, IU/L(median,IQR) 71.0 (48.0 ~ 138.5) 84.5 (56.3 ~ 115.5) 0.801
HCV viral load (≥ vs < 4x105 IU/ml) 17:28 28:6 < 0.001
Liver cirrhosis (yes vs. no) 4:41 6:28 0.313
> 80 % adherence (yes vs. no) 32:13 24:10 0.960
rs12979860 (CC vs. CT + TT) 43:2 24:10 0.002
rs 8099917 (TT vs. GG + GT) 44:1 25:9 0.002
TLR2 mRNA (median,IQR) −1.36 (−2.52 ~ 0.76) 0.82 (0.55 ~ 0.96) 0.001
TLR3 mRNA (median,IQR) −2.66 (−3.13 ~ −1.28) −1.47 (−1.90 ~ −1.27) 0.014
TLR4 mRNA (median,IQR) −1.85 (−2.53 ~ 0.57) 0.66 (0.31 ~ 0.86) < 0.001
TLR7 mRNA (median,IQR) −2.41 (−3.19 ~ −0.07) −0.77 (−1.18 ~ −0.57) 0.008
TLR9 mRNA (median,IQR) −2.44 (−3.17 ~ −1.01) −0.98 (−1.26 ~ −0.84) 0.001
BMI body mass index, ALT alanine aminotransferase, TLR toll like receptor, TLR mRNA expressions were shown as log ratios relative to GAPDH mRNA (log 2 -(ΔCt)).
> 80 % adherence: patients who received more than 80 % of standard dose and duration
Table 2 Comparisons of baseline features of patients with sustained virological response (SVR) and those with non-SVR
Variables SVR (N = 45) Non-SVR (N = 30) P value
Sex (M:F) 19:26 20:10 0.038
Age (median,IQR) 59.7 (51.1 ~ 67.4) 56.6 (45.9 ~ 64.7) 0.176
BMI, Kg/m2 (median,IQR) 23.9 (22.4 ~ 27.1) 23.7 (21.4 ~ 27.8) 0.787
ALT, IU/L(median,IQR) 84.0 (52.0 ~ 134.5) 77.0 (44.8 ~ 14.8) 0.423
Viral load (≥ vs < 4 × 105 IU/ml) 25:20 19:11 0.503
RVR (yes vs. no) 31:14 10:20 0.002
Liver cirrhosis (yes vs. no) 2:43 8:22 0.012
> 80 % adherence (yes vs. no) 32:13 21:9 0.918
rs12979860 (CC vs CT + TT) 43:2 20:10 0.002
rs 8099917 (TT vs GG + GT) 45:0 20:10 < 0.001
TLR2 mRNA (median,IQR) −1.07 (−4.05 ~ −0.74) −0.96 (−3.39 ~ −0.67) 0.304
TLR3 mRNA (median,IQR) −3.39 (−4.53 ~ −2.86) −3.28 (−4.10 ~ −2.90) 0.607
TLR4 mRNA (median,IQR) −1.24 (−4.05 ~ −0.96) −1.02 (−3.54 ~ −0.78) 0.067
TLR7 mRNA (median,IQR) −2.76 (−4.53 ~ −2.19) −2.42 (−4.18 ~ −2.20) 0.545
TLR9 mRNA (median,IQR) −2.85 (−4.57 ~ −2.59) −2.62 (−4.12 ~ −2.47) 0.124
RVR rapid virological response, BMI body mass index, ALT alanine aminotransferase, TLR toll like receptor. TLR mRNA expression levels were shown as log ratios
relative to GAPDH mRNA (log 2 -(ΔCt))
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non-infectious inflammation (Crohn’s disease, gout,
rheumatoid arthritis, autoinflammatory syndromes and
pancreatitis). They found that soluble TLR4 had a simi-
lar capacity for differentiating infectious and non-
infectious inflammation compared to C reactive protein
(CRP), and suggest the possibility to use soluble TLRs
as diagnostic tool in inflammatory conditions [34].
Machida et al. reported that HCV non-structural 5A
(NS5A) protein, which plays a potential role in resist-
ance to IFN-α treatment, transactivates the TLR4 pro-
moter in vitro, resulting in increased transcription of
TLR4 [29].
He et al. enrolled 15 HCV infected patients who had
received a 48-week treatment with peg-IFN and RBV.
They found that baseline PBMC TLR 2 and 3 mRNA
levels were significantly higher in patients with SVR than
in non-responders. They suggested that TLR 2/3, which
was up-regulated in PBMCs, might act as an adjuvant
receptor, increasing not only the sensitivity to HCV
PAMPs but also the sensitivity to INF-α treatment, and
subsequently increased effective antiviral responses [35].
However, the number of cases examined was small.
Yuki et al. reported that low hepatic TLR3 expression
was a predictor of SVR to peg-IFN plus RBV in patients
with HCV genotype 1 [36]. TLRs are known to be intra-
hepatic interferon stimulated genes (ISGs) and these re-
sults were consistent with previous studies which found
that pre-activation of intra-hepatic ISGs was associated
with non-response in HCV-infected patients [37–40].
Activation of the endogenous IFN system in HCV-
infected patients was ineffective in clearing the infec-
tion and even impeded the response to therapy, most
likely by inducing a refractory state in the IFN signaling
pathway [37–40]. However, analyzing gene expression in
liver biopsy specimens requires an invasive procedure.
In this study, we found that mRNA expression of
TLR 2, 3, 4, 7, and 9 was correlated with HCV viral
load. TLR activation upon exposure to HCV may sub-
sequently limit HCV replication [25, 26, 28, 31, 32].
However, HCV can escape host immunity via several
methods and sustain a chronic infection [30, 41, 42].
These interactions between HCV and TLRs may be one
reason for the correlation between TLR expression and
HCV viral load observed in our study.
Conclusion
Low PMBC TLR 4 levels were correlated with RVR,
which indicates that TLR4 may play a critical role in
HCV recognition and activation of innate and adaptive
immunity. mRNA expression of TLRs was correlated
with HCV viral load, which indicates that TLR activation
upon exposure to HCV may subsequently limit HCV
replication.
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